Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
about
Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in miceKey role of tissue plasminogen activator in neurovascular couplingRecombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-AnalysisThe tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humansDelayed postconditioning protects against focal ischemic brain injury in rats.Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusionEmerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic AgentsImpact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicityInsulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamateBlood-brain barrier permeability and tPA-mediated neurotoxicity.Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in ratstPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury.Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPKuPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.Endothelin and the neurovascular unit in pediatric traumatic brain injury.Dopamine prevents impairment of autoregulation after traumatic brain injury in the newborn pig through inhibition of Up-regulation of endothelin-1 and extracellular signal-regulated kinase mitogen-activated protein kinase.Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13Neuroprotection and stroke: time for a compromise.Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.Novel actions of tissue-type plasminogen activator in chronic kidney disease.Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microgliatPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1.Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activationErythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.Emerging neuroprotective drugs for the treatment of acute ischaemic stroke.Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms.tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS.Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI.Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration.Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.Fibrinolysis: from blood to the brain.Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
P2860
Q27320059-C21936BB-8DA2-4ABA-8604-6827EBE439BAQ28512912-1180A967-D10A-4260-8A7F-79710DE8DE17Q28552445-B21B0DEF-1146-4BAA-BB5C-F6DE125101CAQ30528502-58FAF8C8-3FBF-46A6-B660-A76A03D3427DQ33391388-B8C3C993-B8A5-4EB7-8810-251F9DD78C6FQ33600876-AF7BD63B-1614-4234-8028-4726A29B61A9Q33767438-6AEB5EDA-1046-4E2D-AE93-B26A40A3FF39Q33783563-3B40843C-EB35-48DC-B6B2-94558C302426Q34006140-E4961D3C-CA94-4579-BA64-1169EADC23C1Q34018715-B3D7773C-320E-4933-936D-6E4B432F98ACQ34171180-523BBAA6-0A9C-42CB-A088-914B2EDF88E2Q34363696-CFFE62B0-2AE8-482D-9208-F10382932892Q34504984-7A5EC813-69E2-402D-91BD-ECC470F24033Q35217410-E170B683-3226-48EC-8E84-82797B8C5B63Q35580943-BFF2FA95-520C-4CAC-A439-96E6B99B03FCQ35675445-AF19DDF6-8058-4ED0-A08D-071B9F90C422Q35989919-335172A2-C09F-448E-B122-1CA764861B89Q36307742-9493D8DB-4E2C-44AD-AD78-327DEC469162Q36473166-23660201-E261-4E23-9852-E5F337693334Q36512703-3C0ACD0C-2F76-4A40-9762-CAE574D67CF5Q36534737-CED302DF-BBC3-4E8E-9E73-A77411A4688CQ36595057-E55987E3-3BAB-4CDE-8D8F-973BCFBD9737Q36903087-C151BE74-DE2C-420A-9404-7A1DA7A91A3FQ36922560-9BC56C2C-14D0-4BD1-8DF8-F8333C01CE39Q36925788-AB1B3723-7844-4B17-9FDE-9BF7F675C11BQ37115034-4B64CF7D-8551-4CFE-AE71-119C3D010A83Q37192113-E6432DB1-E0F6-4B76-8EC5-9B49B7F9B548Q37272721-6098567D-C210-456F-93B6-E8E371D2B355Q37285884-534C4CD5-5251-490F-B830-D6B61EB77225Q37397703-B10071C1-9278-440B-8567-E18E20C8474FQ38100263-F7B2FDB9-CF74-4B27-9A8B-84F47828000DQ38198639-39A73265-6891-4B81-8832-F5C7513D9C26Q38965982-D602624B-7D47-438C-AA30-B005C6FA2AB8Q39141643-9C112DE8-C3CE-4BE8-89FD-5B688C989713Q41466753-91DB4148-28EA-4E0F-9AB5-ED84B8EF729DQ41962747-AD643B85-12CA-4E4D-AB6E-D0C1A4AA0A55Q46008327-D29C9EC9-D697-4105-B0C8-25A3F6262F9FQ46268137-577E5A41-A6B4-40AD-9371-050D96BF2056Q48106697-AF769966-98AC-404D-ABFE-0371D6C02CA7Q48914597-F16EB831-892B-4743-B6ED-1FA41987207A
P2860
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@en
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@nl
type
label
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@en
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@nl
prefLabel
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@en
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@nl
P2093
P2860
P356
P1433
P1476
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
@en
P2093
Abd Al-Roof Higazi
Douglas B Cines
Douglas H Smith
Saed Akkawi
Taher Nassar
William M Armstead
Xiao-Han Chen
P2860
P2888
P304
P356
10.1038/NN1757
P407
P577
2006-09-01T00:00:00Z